Dr. Madhuri Bajaj, MD

Dr. Bajaj practices at Oncology-Hematology Associates of Central Illinois P C in Peoria, Illinois.

Dr. Bajaj's NPI, 1699883595, was assigned on August 29, 2006. Dr. Bajaj holds Illinois license 036130745.

Dr. Bajaj's primary practice is Oncology-Hematology Associates of Central Illinois P C, at 8940 N Wood Sage Rd, Peoria, IL 61615 in Peoria County. The practice phone is (309) 243-3000.

Dr. Bajaj's primary practice is Oncology-Hematology Associates of Central Illinois P C in Peoria, Illinois. Dr. Bajaj is also affiliated with OSF Saint Francis Medical Center. The medical group on file is Illinois CancerCare. Dmand AI also links Dr. Bajaj to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bajaj practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bajaj's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bajaj is licensed in Illinois.

CMS data shows 133,572 Medicare services from Dr. Bajaj across 75 procedure codes in 2024, for 895 Medicare patients. Medicare paid $1,231,225 for them.

CMS counts 895 Medicare patients who saw Dr. Bajaj in 2024. The largest group is 65 to 74, with 413 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bajaj's median patient age at 71, with 53% women.

In 2024, Dr. Bajaj wrote 2,267 Medicare Part D claims for 276 patients. 78% of them were for generic drugs. CMS names the drug for 1,960 of them, across 45 drugs with 11 or more claims each, at $3,625,108 in total drug cost. In 2023, CMS named 1,638 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Bajaj for performance year 2024, reported as part of a group. Dr. Bajaj accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bajaj as offering telehealth.

Dmand AI links Dr. Bajaj to 2 clinical trials. Conditions studied include Pancreatic Neoplasms and Pancreatic Diseases. Open Payments lists research payments to Dr. Bajaj that name 2 trials.

CMS Open Payments shows 285 general payments to Dr. Bajaj from 33 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 84% of the total. Novartis Pharmaceuticals Corporation paid the most, $519. It also lists 4 research payments totaling $13,061 from 2016 to 2018, naming 2 clinical trials.